Pharmacokinetic, Safety and Tolerability Study of SPARC1028

Trial Profile

Pharmacokinetic, Safety and Tolerability Study of SPARC1028

Phase of Trial: Phase I

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Sun Pharmaceutical Industries
  • Most Recent Events

    • 20 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 30 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016.
    • 15 Dec 2015 Status changed from recruiting to active, no longer recruiting as per record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top